SNY Sanofi
- 48.150
- -0.040-0.08%
- 48.150
- 0.0000.00%
Sanofi News
6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines
6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K: Colletion of Recent Announcements
6-K: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma and Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria
SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
6-K: Dupixent Approved in the EU as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
6-K: Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance
6-K: Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines and Sanofi and CD&R Partner to Fuel Opella's Ambitions in Consumer Healthcare
6-K: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants and Sanofi in discussions to sell a controlling stake in Opella
6-K: Dupixent Approved in China as the First-Ever Biologic Medicine for Patients with COPD and Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis
SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-SANOFI(15.80%)
3: Initial statement of beneficial ownership of securities-10% Owner Sanofi
6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
6-K: Sanofi Reports Strong Second Quarter Results with 10% Sales Growth; 2024 Guidance Upgraded
6-K: 2024 Half-Year Financial Report
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
No Data
